

Tanzania

Support for Vaccine: HPV

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Tanzania							
2. Vaccine grant number: 18-TZA-08f-Y, 1820-TZA-19b-X							
3. Date of Decision Letter: 30 September 2019							
4. Date of the Partnership Framework Agreement: 1 July 2013							
5. Programme title: New Vaccine Support (NVS), HPV, Routine							
6. Vaccine type: HPV							
7. Requested product presentation and formulation of vaccine: HPV Quadrivalent, 1 dose(s) per vial, LIQUID							
8. Programme Duration:¹ 2018-2020							
9. Programme Budget (indicative):² (subject to the terms of the Partnership Framework Agreement, if applicable)							
	2018-2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	13,821,500	1,885,500	-	-	-	-	15,707,000
10. Vaccine introduction grant							
Approval							
Year		Grant Number		Amount (US\$)			
2018		18-TZA-08f-Y		1,719,890			
Disbursement							
Disbursement date				Amount (US\$)			
27 November, 2017				1,719,890			
11. Product switch grant							
Not applicable							
12. Indicative Annual Amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)							
Type of supplies to be purchased with Gavi funds	2018-2019		2020			2021	

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

	Number of vaccine doses		414,200	-						
	Annual Amounts (US\$)	13,821,500	1,885,500	-						
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.									
14. Self-procurement:	Not applicable									
15. Co-financing obligations:	According to the co-financing policy, the Country falls within the group: Initial self-financing									
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.										
Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024					
Number of vaccine doses	19,100	-	-	-	-					
Number of AD syringes	-	-	-	-	-					
Number of re-constitution syringes	-	-	-	-	-					
Number of safety boxes	-	-	-	-	-					
Value of vaccine doses (US\$)	85,643	-	-	-	-					
Total co-financing payments (US\$) (including freight)	87,000	-	-	-	-					
16. Operational support for campaigns:	Not applicable									
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>					Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates									
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020									
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat									

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30 September 2019